Literature DB >> 2810071

Mean residence time for drugs subject to enterohepatic cycling.

T A Shepard1, G F Lockwood, L J Aarons, I D Abrahams.   

Abstract

A physiologically realistic model of enterohepatic cycling (EHC) which includes separate liver and gallbladder compartments, discontinuous gallbladder emptying and first-order absorption from both an oral formulation and secreted bile (kapo and kab, respectively) has been developed. The effect of EHC on area under the first-moment curve (AUMC) of drug concentration in plasma and on parameters derived from the AUMC was investigated. Unlike AUC, AUMC is dependent on the time and time-course of gallbladder emptying, increasing as the interval between gallbladder emptying increases. Consequently, mean residence time (MRT) is also a time-dependent parameter. Analytical solutions for MRTiv and MRTpo were derived. Mean absorption time (MAT = MRTpo - MRTiv) is also time-dependent, contrary to findings previously published for a model of EHC with a continuous time lag. MAT is also dependent on kapo, kba and the hepatic extraction ratio. The difference between MRTpos for two formulations with unequal kapo values may deviate from the difference in the inverse of their absorption rate constants. Implications for design and interpretation of pharmacokinetic studies include (i) MAT values may be dominated by the time-course of recycling rather than the time-course of the initial absorption, depending on the extent of EHC and (ii) the unpredictable nature of the time of gallbladder emptying will contribute to intrasubject variability in derived parameters during crossover studies. Knowledge of the extent of EHC is invaluable in deciding whether modification of the in vitro release characteristics of an oral formulation will have any effect on the overall time-course of absorption in vivo. Techniques to monitor or control gallbladder emptying may be helpful for reducing variability in pharmacokinetic studies for compounds which are extensively cycled in bile.

Entities:  

Mesh:

Year:  1989        PMID: 2810071     DOI: 10.1007/bf01061900

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  15 in total

1.  Influence of cholestasis on drug elimination: pharmacokinetics.

Authors:  L I Harrison; M Gibaldi
Journal:  J Pharm Sci       Date:  1976-09       Impact factor: 3.534

2.  An equation for the systemic availability of drugs undergoing simultaneous enterohepatic cycling, first-pass metabolism, and intestinal elimination.

Authors:  T A Shepard; R H Reuning
Journal:  Pharm Res       Date:  1987-06       Impact factor: 4.200

3.  Interpretation of area under the curve measurements for drugs subject to enterohepatic cycling.

Authors:  T A Shepard; R H Reuning; L J Aarons
Journal:  J Pharm Sci       Date:  1985-02       Impact factor: 3.534

4.  Mean residence time in peripheral tissue: a linear disposition parameter useful for evaluating a drug's tissue distribution.

Authors:  P Veng-Pedersen; W Gillespie
Journal:  J Pharmacokinet Biopharm       Date:  1984-10

5.  Estimation of area under the curve for drugs subject to enterohepatic cycling.

Authors:  T A Shepard; R H Reuning; L J Aarons
Journal:  J Pharmacokinet Biopharm       Date:  1985-12

6.  A time-lag model for pharmacokinetics of drugs subject to enterohepatic circulation.

Authors:  J L Steimer; Y Plusquellec; A Guillaume; J F Boisvieux
Journal:  J Pharm Sci       Date:  1982-03       Impact factor: 3.534

7.  Pharmacokinetics of doxycycline reabsorption.

Authors:  P V Pedersen; R Miller
Journal:  J Pharm Sci       Date:  1980-02       Impact factor: 3.534

8.  Pharmacokinetics and bioavailability of cimetidine in humans.

Authors:  P V Pedersen; R Miller
Journal:  J Pharm Sci       Date:  1980-04       Impact factor: 3.534

9.  Pharmacokinetic interpretation of the enterohepatic recirculation and first-pass elimination of morphine in the rat.

Authors:  B E Dahlström; L K Paalzow
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

10.  Pharmacokinetics and bioavailability of ranitidine in humans.

Authors:  R Miller
Journal:  J Pharm Sci       Date:  1984-10       Impact factor: 3.534

View more
  7 in total

Review 1.  Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.

Authors:  Michael S Roberts; Beatrice M Magnusson; Frank J Burczynski; Michael Weiss
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

3.  An experimental design strategy for quantitating complex pharmacokinetic models: enterohepatic circulation with time-varying gallbladder emptying as an example.

Authors:  Y M Wang; R H Reuning
Journal:  Pharm Res       Date:  1992-02       Impact factor: 4.200

4.  Analysis of enterohepatic circulation of cefixime in rat by fast inverse Laplace transform (FILT).

Authors:  K Yamaoka; M Kanba; Y Toyoda; Y Yano; T Nakagawa
Journal:  J Pharmacokinet Biopharm       Date:  1990-12

5.  Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes.

Authors:  T M Davis; F Daly; J P Walsh; K F Ilett; J P Beilby; L J Dusci; P H Barrett
Journal:  Br J Clin Pharmacol       Date:  2000-03       Impact factor: 4.335

6.  Physiologically based structure of mean residence time.

Authors:  Mária Durišová
Journal:  ScientificWorldJournal       Date:  2012-04-01

7.  Effect of efavirenz-based ART on the pharmacokinetics of rifampicin and its primary metabolite in patients coinfected with TB and HIV.

Authors:  Jesper Sundell; Emile Bienvenu; Angela Äbelö; Michael Ashton
Journal:  J Antimicrob Chemother       Date:  2021-10-11       Impact factor: 5.790

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.